Javtor/biomedical-topic-categorization-validation

PMID int64 35.7M 36.4M	Title/Abstract stringlengths 22 8.78k	MeshTerms stringlengths 7 101	SemanticTypes stringlengths 4 64
36,286,961	antibodi phosphatidylserineprothrombin complex diagnosi antiphospholipid syndrom determin signific antibodi phosphatidylserineprothrombin complex apspt patient system lupus erythematosus sle antiphospholipid syndrom ap	D016736;D008180;D013927	T047;T046
36,286,960	burden progress psoriat arthriti russian regist data psoriat arthriti psa complex immun mediat diseas third patient psoriasi pso inflammatori lesion musculoskelet system peripher joint axial structur extra articular manifest dactyl enthes nail pso uveiti inflammatori bowel diseas	D015535;D011565	T047
36,286,959	success psychopharmacotherapi anxieti depress disord improv function limit patient rheumatoid arthriti compar chang function limit patient rheumatoid arthriti ra comorbid anxieti depress disord add treat convent synthet diseas modifi antirheumat drug csdmard alon combin biolog dmard bdmard andor psychopharmacotherapi ppt determin predictor haq treatment respons	D001172;D018501;D001688;D003866	T121;T047;T123;T048
36,286,958	evalu associ polymorph cypc gene efficaci safeti ketorolac patient postop pain syndrom evalu possibl associ cypc gene polymorph clinic efficaci safeti ketorolac relat postop pain	D020910;D010149	T121;T047;T184;T109
36,286,957	janus kinas inhibitor immunoinflammatori rheumat diseas despit great advanc diagnosi treatment immunoinflammatori rheumat diseas led signific improv prognosi mani patient fundament medic problem patholog restor qualiti life reduct mortal popul level far resolv serv stimulus studi new approach pharmacotherapi ivrd one associ use low molecular weight chemic synthes drug inhibit intracellular signal molecul janus kinas modern advanc regard use janus kinas inhibitor treatment immunoinflammatori rheumat diseas covid consid	D000075242;D000086382;D012216;D000076742	T121;T047;T067
36,286,954	format cardiolog ussr call founder xx centuri special clinic area gradual emerg general bodi intern medicin among cardiolog becam one first literatur yet explicit consid question consid founder russian cardiolog data suggest dd pletnev gf lang nd strazhesco vf zelenin al myasnikov ei chazov exhaust nomin composit founder cardiolog ussr	D002309	T091
36,286,953	featur intestin condit patient new coronavirus infect covid infect may present gastrointestin lesion patient one target organ sar cov virus intestin pathogenesi intestin damag new coronavirus infect remain unclear requir depth studi possibl mechan includ direct cytotox effect virus persist reduct butyr produc bacteria side effect drug clostridioid difficil infect microvascular thrombosi immun mediat inflammatori reaction intestin common symptom intestin damag coronavirus infect acut phase post covid period diarrhea impact mani aggress factor intestin form long term function disord caus onset organ diseas treatment aim possibl caus intestin damag clostridioid difficil well reduc inflamm restor intestin permeabl cytoprotect mucos cell replenish butyr acid defici choos therapi intestin disord prefer given drug pleiotrop effect order influenc various possibl pathogenet mechan	D000086402;D000086382	T005;T067;T047
36,286,952	problem associ effect pharmacotherapi elder patient geriatr review world older popul grow dramat time ensur appropri high standard live elder reduc morbid disabl geriatr patient one main object modern healthcar system howev chang associ bodi age necessit applic novel approach correct pharmacotherapi usag special dosag form medicin product provid appropri therapeut effect facilit use present review consid sever featur pharmacotherapi geriatr patient	D005853	T090;T091
36,286,951	stress induc arteri hypertens stress consid one factor associ develop mani diseas includ cardiovascular system histori studi stress risk factor hypertens began first half th centuri continu introduct hour blood pressur monitor abpm clinic practic turn normotens stabl hypertens latent hypertens mask clinic bp within normal rang arteri hypertens record accord abpm andor self monitor bp white coat hypertens increas bp visit doctor normal valu blood pressur accord abpm self monitor bp current variant latent hypertens classifi stress induc arteri hypertens sever model propos studi stress two common clinic studi karasek model base imbal job demand job decis latitud siegrist model base imbal effort reward studi attempt made link increas bp paramet stress respons exampl hormon level genet predisposit review discuss signific studi stress induc arteri hypertens publish date	D006973;D059466	T047
36,286,950	rehabilit patient chronic thromboembol pulmonari hypertens patient pulmonari hypertens ph recommend physic rehabilit long time fact physic activ discourag nowaday posit regard exercis patient ph chang studi shown safeti effect exercis patient studi publish date rehabilit patient ph assess effect exercis toler review provid overview publish studi conclus effect rehabilit patient chronic thromboembol hypertens complex therapi use medic surgic method treatment rehabilit inclus rehabilit complex treatment allow achiev patient highest possibl toler physic activ increas function class qualiti life restor work capac	D006976;D011655;D000800	T061;T047;T046
36,286,949	erdheim chester diseas cardiac involv case report erdheimchest diseas ecd rare non langerhan histiocytosi multisystem inflammatori infiltr consist monocytesmacrophag reactiv microenviron fibrot field cardiovascular involv one frequent manifest ecd lead life threat complic articl report clinic case ecd cardiac involv young patient	D031249	T047
36,286,948	pathomorpholog clinic characterist blastic plasmocytoid dendrit cell neoplasm case report paper reveal case date blastic plasmacytoid dendrit cell neoplasm present inform demonstr morpholog immunohistochem data clinic manifest	D012878;D009196;D019337	T191
36,286,947	asept nasal septal abscess patient ulcer coliti two case report case report ulcer coliti uc may associ differ extra intestin manifest eim often difficult diagnos treat may complic cours diseas eim multidisciplinari problem encount doctor various special howev mani incid eim patient uc remain unknown coexist uc asept nasal abscess ana uncommon describ two case ana young femal patient uc ana run parallel intestin diseas activ led necrosi septal cartilag moreov pyoderma gangrenosum describ one asept abscess syndrom kept mind microbi factor identifi diagnosi clear patient improv appropri antibacteri therapi ana present rare complic uc	D003093;D017511;D012141	T047
36,286,946	peculiar hemostasi patient covid analysi dynam differ stage clot format lysi patient differ covid sever	D000086382;D013927	T047;T046;T067
36,286,945	new opportun prevent anti inflammatori therapi manag patient moder sever covid specif featur new coronavirus infect covid high risk hyperinflammatori respons cytokin storm develop under pathogenesi sever life threaten condit determin diseas outcom pathophysiolog featur covid justifi search effect drug capabl control hyperinflammatori respons	D000893;D000086382	T121;T047;T067
36,286,944	data russian sever asthma registri rsar creation russian regist patient sever asthma obtain data popul characterist patient sever asthma sa preval sa phenotyp treatment outcom degre diseas control	D001249;D001688;D018927	T123;T047;T121
36,286,943	pregnanc paroxysm nocturn hemoglobinuria surviv life pregnanc paroxysm nocturn hemoglobinuria pnh patient histor high risk situat combin chronic complement mediat hemolysi caus diseas physiolog activ complement system pregnanc signific worsen prognosi life long time effect method pnh treatment pregnanc patient seem extrem riski signific increas risk life threaten complic advent target therapi eculizumab turn prognosi diseas upsid patient began surviv also live compar healthi peopl compar analysi cours outcom pregnanc patient pnh treat eculizumab patient without target therapi carri	D006457	T047
36,286,942	pharmacoeconom analysi use fix combin budesonideformoterol patient asthma health care system russian feder evalu budgetari impact use budesonid formoterol symbicort turbuhal mainten therapi real clinic practic compar standard therapi asthma vari sever mild asthma demand salbutamol moder sever asthma drug salmeterol fluticason salbutamol demand	D000069502;D001249	T121;T047;T109
36,286,941	preval clinic associ iron defici patient decompens heart failur depend diagnost criteria use iron defici compar frequenc iron defici id patient decompens heart failur hf defin intern guidelin criterion ferritin ngml ferritin ngml tsat criterion bone marrow biopsi criterion tsat serum iron moll criterion b evalu effect id diagnos basi differ id criteria nt pro bnp sst crp level new york heart associ nyha function class fc distribut group id without id	D000090463;D006333	T047;T046
36,286,940	withdraw syndrom tyrosin kinas inhibitor discontinu patient chronic myeloid leukemia withdraw syndrom ws musculoskelet pain discontinu tyrosin kinas inhibitor tki patient chronic myeloid leukemia cml describ treatment free remiss tfr studi pathophysiolog mechan predispos factor ws well establish	D059352;D015464	T033;T191
36,286,939	multipl myeloma respons treatment surviv patient accord interim analysi russian observ retrospect prospect multicent cohort studi multispect primari object interim analysi multispect studi evalu short term efficaci treatment long term outcom cohort primari pretreat patient multipl myeloma mm receiv treatment actual clinic practic various region russian feder secondari object descript main characterist patient analysi common use therapi regimen st later line sequenc chang evalu respons therapi addit object includ evalu effect new covid coronavirus infect cours mm patient	D009101;D000086382;D018380	T061;T047;T191;T067
36,286,938	ospit outcom coronari arteri bypass graft patient coronari heart diseas previous percutan coronari intervent evalu frequenc hospit cardiovascular event group patient stabl angina underw percutan coronari intervent pci stent arteri coronari bypass surgeri previous myocardi revascular	D062645;D003324;D060050;D009203	T061;T047
36,286,937	combin use grace ac risk score comorbid indic increas effect hospit mortal risk assess patient acut coronari syndrom assess possibl use comorbid indic togeth grace global registri acut coronari event scale assess risk hospit mortal acut coronari syndrom ac	D054058;D062645	T061;T047
36,286,936	chronic kidney diseas outpati arteri hypertens clinic characterist treatment efficaci accord nation registri im investig clinic characterist qualiti treatment accord nation guidelin patient arteri hypertens ah chronic kidney diseas observ primari health care	D003924;D051436;D006973	T047
36,286,935	biochem marker thrombot complic acut period ischem stroke studi profil biochem marker hemostasi system clarifi role relationship pathogenesi develop thrombot complic tc ischem stroke associ assess possibl diagnost applic	D000083242;D000933;D013927	T121;T047;T046
36,286,934	se differ treatment acut coronari syndrom patient data feder registri acut coronari syndrom manag patient acut coronari syndrom ac usual univers regardless gender age ethnic often practic gender age influenc medic decis patient receiv proper medic care medic care patient ac analyz gender accord feder regist ac data	D054058;D062645	T061;T047
36,286,933	chronic thromboembol pulmonari hypertens pathogenesi choic treatment tactic present data pathogenesi chronic thromboembol pulmonari hypertens cteph serv rational approach choic treatment cteph usual begin persist obstruct larg andor medium pulmonari arteri organ thrombi impair lysi thrombi may associ abnorm fibrinolysi hematolog autoimmun diseas molecular process under lesion small vessel fulli understand degre small vessel diseas signific impact sever cteph postop outcom cteph treatment evolv develop three direct pulmonari endarterectomi balloon angioplasti pulmonari arteri use specif therapi use pulmonari arteri hypertens paper demonstr possibl multimod approach treatment categori patient	D006976;D011655;D000800	T061;T047;T046
36,286,931	hypnotherapi increas well emot well broad term refer happi posit social relationship life balanc pursuit posit goal emot well shown reduc risk death near cohen et al lead articl na et al explor issu report pilot studi hypnot relax therapi well hrt wb find demonstr particip achiev high level well flourish addit innov studi sever articl includ increas access scale measur hypnotiz french apelian russian kvitchasti spanish muiz et al kaso et al explor role hypnotiz regard skin conduct orient respons scr respons differ type suggest final cordi rasch explor role hypnotiz accur percept sleep find suggest sleep depth may associ slow wave sleep interocept abil accur perceiv sleep depth depend hypnotiz togeth studi identifi new applic clinic hypnosi increas avail scale measur hypnotiz across cultur understand hypnotiz	D006990	T061
36,286,858	histori special clinic intern diseas role ss zimnitski kazan format nephrolog ussr russian nephrolog like clinic disciplin pass two stage histor develop first stage becam isol import area scientif research within framework soviet clinic intern diseas second stage becam independ scientif educ clinic disciplin medic specialti articl show role kazan internist ss zimnitski one founder nephrolog ussr first stage format one leader function direct soviet clinic medicin	D009398;D015510	T091
36,286,857	kidney damag caus lead exposur histor aspect articl present histor analysi public devot lead intox kidney damag develop contact lead shown one manifest occup intox metal toxic nephropathi	D007674;D007855;D009784;D016273	T047;T037
36,286,856	modern view complement system role membran nephropathi membran nephropathi mn immun mediat glomerular diseas common caus adult nephrot syndrom mn proteinuria develop podocyt damag due complement system activ respons subepitheli deposit immun complex contain various auto exogen antigen membran attack complex mac termin product complement pathway activ classic lectin altern play lead role complement mediat podocyt damag thus far main pathway complement activ lead format mac mn establish review highlight current evid various complement pathway activ develop mn well recent establish new molecular mechan complement mediat podocyt damag	D015433	T047
36,286,855	diagnost treatment difficulti kidney damag patient general sarcoidosi covid case report present clinic observ reflect difficulti differenti diagnosi progress kidney damag patient sarcoidosi undergon new coronavirus infect differenti circl includ interstiti nephriti exacerb under diseas acut drug induc kidney injuri acut glomerulonephr nephrobiopsi confirm diagnosi acut sarcoid tubulointerstiti nephriti acut tubular necrosi time administr corticosteroid led control sarcoidosi process restor kidney function	D000086382;D009395;D012507	T047;T067
36,286,854	impact kidney biopsi manag patient rheumatolog depart retrospect studi kidney involv common manifest system autoimmun rheumat diseas kidney biopsi gold standard diagnosi kidney diseas howev method yet becom standard care rheumatolog practic	D012219;D008180	T047;T091
36,286,853	soy protein part low protein diet new direct cardio nephroprotect patient b stage chronic kidney diseas prospect random control clinic studi establish use low protein diet lpd combin ketoanalogu ka essenti amino acid contribut cardio nephroprotect chronic kidney diseas ckd moreov shown replac part anim protein soy protein sp diet contribut pronounc nephro cardioprotect ckd howev data avail literatur main repres experiment studi	D018753;D051436	T061;T047
36,286,852	new opportun neuroprotect therapi patient acut earli recoveri period ischem stroke evalu efficaci safeti brainmax comparison ethylmethylhydroxypyridin succin trimethylhydrazinium propion patient ischem stroke acut earli recoveri period	D002545;D000083242;D020521	T047;T046
36,286,851	risk factor kidney injuri patient covid determin incid risk factor acut kidney injuri aki russian cohort patient covid	D000086382;D058186;D051436	T047;T037;T067
36,286,850	evalu hemostasi disord use thrombodynam test patient chronic glomerulonephr nephrot syndrom nephrot syndrom ns accompani risk thrombot complic due hypercoagul routin laboratori test sensit enough detect disord therefor use integr coagul test includ new thrombodynam test tt patient ns high relev	D009404;D019851;D013927;D005921	T047;T046
36,286,849	clinic signific serum level osteoproteherin sclerostin assess vascular calcif chronic kidney diseas stage clarifi mechan effect osteoprotegerin opg sclerostin vascular calcif state cardiovascular system chronic kidney diseas ckd	D061205;D051436	T047
36,286,848	urinari biomark kidney injuri patient treat anti vegf drug antiangiogen drug wide use oncolog practic aim inhibit angiogenesi despit high antitumor efficaci use may limit nephrotox therefor search earli biomark kidney damag remain relev preserv favor safeti profil therapi	D058186;D007674;D051437	T047;T037
36,286,847	remiss progress c glomerulopathi analyz outcom c glomerulopathi c gp determin associ factor	D015432;D007674	T047
36,286,846	lupus nephriti xxi centuri lupus nephriti ln common organ lesion system lupus erythematosus sle develop patient due immunosuppress therapi surviv patient sle increas signific past year proport sever kidney damag death structur decreas howev ln relaps complic immunosuppress acceler atherogenesi concomit diseas lead accumul organ damag increas risk death articl consider place kidney damag sle risk factor ln develop main renal histopatholog chang identifi number issu need address optim treatment improv ln long term outcom includ revis pathogenet therapi regimen restrict glucocorticosteroid prescrib drug steroid spare activ integr new drug ln treatment wider use modern nephroprotect capabl	D008181;D008180;D007676	T047
36,286,844	assess antitumor antiprolif efficaci detect protein protein interact cancer cell tumor spheroid compar two dimension cell cultur spheroid consid suitabl vitro model drug discoveri research studi drug activ base differ cell cultur procedur describ procedur use obtain tumor spheroid hang drop ultra low attach plate method analyz antiprolif antitumor efficaci differ chemotherapeut agent includ peptidomimet appli method breast lung cancer cell line bt mcf calu also describ proxim ligat assay cell spheroid model detect protein protein interact egfr wiley period llc basic protocol growth spheroid use hang drop method basic protocol growth spheroid use ultra low attach plate support protocol cell viabil assay tumor spheroid support protocol antiprolif antitumor studi tumor spheroid support protocol proxim ligat assay cell deriv spheroid	D057786;D008175	T121;T191
36,286,813	page histori therapeut school central institut improv doctor russian medic academi continu profession educ therapeut scientif pedagog school form central institut advanc train physician cardiolog school prof dmitri pletnev school clinic hematolog emerg care prof alexand n kryukov school dietet gastroenterolog prof manuel pevzner school hematolog prof joseph kassirski mark th anniversari birth outstand therapist academician ussr academi medic scienc major general medic servic prof miron vovsi along fact ms vovsi belong scientif pedagog school cardiolog prof dd pletnev manag creat ms vovsi one creator modern militari field therapi expand understand pathogenesi nephriti pneumonia coronari heart diseas hypertens heart failur introduc new method diagnos treat therapeut patholog lost relev today	D004517;D010820	T065;T097
36,286,812	practic guidelin diagnosi treatment transthyretin amyloid cardiomyopathi attr cm transthyretin cardiac amyloidosi paper summar data updat intern protocol guidelin diagnosi transthyretin amyloid cardiomyopathi attr cm invas non invas diagnosi techniqu combin briefli review evidentiari foundat diagnost option tool analyz paper describ custom algorithm sequenti diagnosi differenti diagnosi patient suspect attr cm allow combin clinic sign diagnost find along awar primari care provid red flag diseas visual criteria well provid inform patient possibl perform therapi attr amyloidosi risk delay diagnosi propos algorithm enabl time patient rout prescrib specif treatment	D000686;D009202	T047
36,286,811	risk develop cardiovascular diseas bipolar disord biolog factor therapi bipolar disord bd one common mental disord character altern episod maniahypomania depress well possibl develop mix condit correct time diagnosi bd import due presenc high suicid risk high predisposit develop cardiovascular diseas cvd risk cvd higher mental disord	D001714;D002318;D019161	T121;T047;T109;T048
36,286,810	manag iron defici chronic heart failur iron defici frequent patient chronic heart failur chf preval frequenc vari depend studi group presenc iron defici limit erythropoiesi lead develop anemia time patient chf regardless gender race left ventricular eject fraction lvef observ studi demonstr higher preval iron defici women patient higher nyha new york heart associ function class decreas lvef increas brain natriuret peptid nt probnp increas high sensit c reactiv protein iron defici anemia patient chf independ associ decreas exercis capac hospit chf increas overal mortal mortal cardiovascular diseas clinic signific iron defici requir need diagnos iron metabol patient chf current guidelin diagnosi treatment chf indic need determin level ferritin satur transferrin patient suspect diagnosi heart failur use oral iron therapi patient chf demonstr low efficaci correct condit accord clinic trial time use intraven iron therapi safe improv symptom exercis capac qualiti life patient heart failur reduc eject fraction iron defici shown intern placebo control trial meta analys use iron carboxymaltos improv chf symptom exercis capac qualiti life patient chf lvef intraven iron therapi also shown reduc readmiss chf patient lvef recent hospit worsen chf	D007501;D000090463	T123;T196;T121;T047
36,286,809	sglt inhibitor acut decompens heart failur know current worldwid preval heart failur grow combin cardiovascular condit determin poor prognosi patient furthermor acut decompens heart failur associ low surviv rate most caus target organ damag effect earli administr sglt inhibitor renal function patient acut decompens heart failur studi determin possibl improv respons treatment well partial complet recoveri renal function goal review synthes current avail evid use sglt inhibitor patient acut decompens heart failur systemat search studi publish analysi carri follow databas web scienc scopus pubmedmedlin	D000077203;D003924;D006333	T121;T047;T046;T109
36,286,808	non compact right ventricular myocardium diagnost clinic featur review non compact right ventricular myocardium rare type cardiomyopathi usual result arrest myocardi develop embryogenesi diseas character excess promin trabecul deep inter trabecular recess ventricular wall might compon biventricular non compact cardiomyopathi isol form articl present review literatur clinic radiat diagnost non compact right ventricular myocardium present issu differenti diagnosi	D004452;D009202	T060;T047
36,286,807	role cardiac magnet reson imag defin prognosi patient acut st segment elev myocardi infarct part assess diseas prognosi current incid congest heart failur st segment elev myocardi infarct stemi tend increas reperfus therapi still effect method reduc infarct size therefor high unmet need novel cardioprotect treatment would improv outcom patient recent advanc cardiovascular magnet reson cmr method enabl identif certain new infarct characterist associ develop heart failur sudden cardiac death characterist help identifi new group high risk patient use target novel cardioprotect treatment part review summar novel cmr base characterist myocardi infarct role prognost stratif stemi patient	D000072657;D062645;D009203;D006333	T061;T047;T046
36,286,806	chronic inflammatori demyelin polyneuropathi acut onset clinic case chronic inflammatori demyelin polyneuropathi cidp heterogen treatabl dysimmun neuropathi varieti clinic form cours diseas challeng proper diagnosi earli treatment quarter case cidp start acut mimick guillainbarr syndrom earli diagnosi especi import regard differ treatment prognosi condit articl present clinic case acut onset cidp detail analysi differenti diagnosi acut chronic immun mediat neuropathi	D020277;D020275	T047
36,286,805	rare clinic case patient pulmonari hypertens associ hereditari hemorrhag telangiectasia case report articl describ rare clinic case patient pulmonari hypertens associ hereditari hemorrhag telangiectasia discuss issu treatment choic patient present clinic case interest pulmonari hypertens initi reveal hereditari natur confirm oslerweberrendu diseas diagnos	D013683;D006976	T047;T046
36,286,804	myocardi scintigraphi tc pyrophosph diagnosi cardiac amyloidosi place diagnost algorithm featur implement interpret studi articl summar current experi nuclear medicin depart chazov nation medic research center cardiolog implement myocardium scintigraphi mtc pyrophosph differenti diagnosi type cardiac amyloidosi caus fals posit equivoc non diagnost result analyz possibl way elimin mistak includ modifi protocol planar tomograph research optim whole diagnost algorithm amyloidosi heart discuss	D055414;D009202;D000686	T060;T047
36,286,803	problem opportun improv diagnosi asthma chronic obstruct pulmonari diseas russia resolut advisori board asthma chronic obstruct pulmonari diseas remain major problem medicin still need improv level qualiti diagnosi diseas primari care physician general practition therapist involv wide activ process simplifi diagnosi special questionnair develop use real clinic practic approach bring statist data closer true preval diseas improv qualiti treatment	D029424;D001249	T047
36,286,802	possibl improv treatment chronic heart failur accord result multicent observ studi byheart studi efficaci safeti exogen phosphocreatin ef patient chronic heart failur chf	D011788;D006333	T078;T047;T046
36,286,801	zonulin fabp marker enterocyt damag celiac diseas evalu level serum fabp fatti acid bind protein protein bind fatti acid fecal zonulin marker permeabl mucous membran small intestin celiac patient	D002446	T047
36,286,800	predict valu qrs complex durat patient chronic heart failur atrial fibril retrospect studi studi featur clinic cours prognosi patient chronic heart failur low eject fraction hfref atrial fibril af depend width qrs complex	D006333;D001281	T047;T046
36,286,799	organ pneumonia pulmonari manifest post covid syndrom featur diagnosi treatment treatment patient long term persist symptom covid urgent problem clinician around world one signific manifest post covid syndrom organ pneumonia usual treat corticosteroid paper present clinic case typic cours post covid organ pneumonia patient without previous lung diseas risk factor diagnost method treatment option group patient also discuss	D000086382;D011014	T047;T050;T067
36,286,798	proinflammatori laboratori predictor pneumonia ischem stroke patient prospect studi bacteri pneumonia frequent complic ischem stroke hospit stage search prognost laboratori marker pneumonia remain urgent task allow individu approach treatment rehabilit patient	D000083242;D011014;D054497;D020521	T047;T116;T050;T126
36,286,797	new approach diagnosi lung lesion patient covid lung ultrasound protocol versus ct scan develop protocol ultrasound diagnost covid pneumonia assess diagnost capabl method comparison comput tomographi ct	D000086382	T047;T067
36,286,796	relationship level l preval atherosclerosi among young patient hyperlipoproteinemia independ caus risk factor atherosclerot cardiovascular diseas ascvd correl lipoprotein lp inflamm vessel wall activ studi past year c reactiv protein crp play import role ascvd	D050197;D019161;D006951	T121;T047;T046;T109
36,286,795	transthyretin amyloid cardiomyopathi featur histolog diagnosi studi design compar effici specif featur transthyretin amyloid stain differ histolog dye thus assess suitabl diagnost purpos	D028227;D009202	T047
36,286,794	prognost signific equival densiti calcium deposit coronari arteri men osteopen syndrom prior coronari arteri bypass graft prospect studi determin clinic prognost valu equival densiti calcium deposit edcd coronari arteri patient stabl coronari heart diseas chd concomit osteopen syndrom os coronari arteri bypass graft cabg base five year follow	D002118;D003324	T123;T196;T121;T047
36,286,793	molecular cardiolog decod genet natur mechan diseas develop introduct clinic recent decad advanc molecular biolog led chang understand inherit mechan develop cardiolog diseas predomin genet origin hypertroph dilat cardiomyopathi famili hypercholesterolemia etc knowledg made possibl develop fundament new drug intervent program detect cardiac diseas predomin genet origin creat includ genet counsel test compet area becom necessari part cardiologist job	D002311;D002309	T047;T091
36,286,765	histori vectorcardiographi past present futur vector concept analysi electr signal heart began use dawn develop electrocardiolog sever decad vectorcardiographi develop parallel electrocardiographi reach peak period cool experienc resurg sinc earli becam possibl mathemat synthes vectorcardiogram vcg digit electrocardiogram lead vcg reflect phenomena electrocardiographi allow calcul visual number three dimension characterist electr signal heart articl describ main mileston develop vcg histori intern cooper area contribut domest scientist field scienc modern promis area research relat vector concept analysi electr signal heart briefli reflect	D014672;D004562	T060;T074
36,286,764	heart failur obes obes independ predictor cardiovascular diseas cvd includ heart failur hf nevertheless numer studi shown patient cvd overweight slight obes better short term moder prognosi thinner patient cvd phenomenon call obes paradox understand obes paradox import patient hf given high preval obes patient hf articl present overview clinic studi devot studi obes risk factor hf pathogenesi hf obes highlight issu obes paradox treatment obes categori patient	D006333;D002318	T047;T046
36,286,763	patent foramen oval caus recurr embol stroke case report clinic case young patient recurr ischem stroke present problem diagnost embol stroke discuss set algorithm identifi patient patent foramen oval probabl caus embol stroke detail consider imag diagnost method possibl includ hypothesi probabl sourc cardioembol patent foramen oval present recommend secondari prevent recurr ischem stroke associ patent foramen oval provid also consid issu antithrombot treatment	D054092;D000083262;D020521	T019;T047
36,286,762	preval combin function dyspepsia irrit bowel syndrom meta analysi studi use rome iii iv criteria systemat data preval combin function dyspepsia fd irrit bowel syndrom ib use rome iiiiv criteria	D004415;D043183;D005767	T184;T047
36,286,761	mechan circulatori support refractori cardiogen shock retrospect regist studi cardiogen shock cs one main caus death patient acut myocardi infarct ami mortal cs remain high despit introduct myocardi revascular use modern medic use mechan circulatori support mcs promis could reduc mortal patient ami cs	D012770;D009203	T047;T046
36,286,760	impact anxieti disord adher anticoagul therapi patient atrial fibril evalu impact anxieti disord adher anticoagul therapi act patient atrial fibril af	D001281	T047;T046
36,286,759	effect cardiac contractil modul patient chronic heart failur atrial fibril result month follow evalu efficaci safeti effect prognosi cardiac contractil modul ccm patient chronic heart failur chf reduc left ventricular eject fraction atrial fibril compar group optim drug therapi odt month follow	D001281;D006333	T047;T046
36,286,758	ectop obes patient without manifest cardiovascular diseas regul frequenc clinic characterist determin frequenc distribut characterist ectop obes patient without manifest cardiovascular diseas	D002318;D006973	T047
36,286,757	featur vectorcardiogram patient hypertens complic chronic heart failur reduc left ventricl eject fraction explor featur vectorcardiogram vcg patient essenti hypertens complic chronic heart failur reduc left ventricular eject fraction chfrlvef	D006333;D001281;D006973	T047;T046
36,286,756	remot electrocardiogram telemonitor endovascular intervent coronari arteri evalu effect new system telemetr electrocardiogram ecg monitor patient endovascular intervent ei coronari arteri ca	D003331;D004562	T060;T023;T074
36,286,755	atorvastatin effect prevent contrast induc acut kidney injuri comput tomographi contrast media assess role atorvastatin frequenc contrast induc acut kidney injuri ci aki patient cardiovascular diseas cvd undergo comput tomographi ct intraven contrast media	D019161;D002318;D058186	T121;T047;T037;T109
36,286,754	guid light diagnosi chronic thromboembol pulmonari hypertens flow patient pulmonari embol decemb expert council held determin posit expert differ specialti regard reason low level diagnosi chronic thromboembol pulmonari hypertens cteph real clinic practic pandem new coronavirus infect possibl way improv detect patient pulmonari embol pe histori reason low level diagnosi cteph insuffici level knowledg specialist especi primari care physician lack clear regulatori document expert center manag categori patient primari diagnosi cteph pandem strengthen widespread use telemedicin consult primari care physician specialist expert center maxim role echocardiographi comput tomographi ct differenti diagnost tool dyspnea particular patient covid increas detect rate cteph diagnost vigil requir patient risk factor episod venous thromboembol improv screen cteph necessari creat algorithm monitor patient pe provid educ activ includ media creat materi patient access inform regulatori document design circl respons specialist engag long term monitor patient pe educ program need primari care physician cardiologist physician come field view patient cteph introduct program creat expert center monitor manag patient possibl perform ventil perfus lung scintigraphi cardiopulmonari stress test ct right heart catheter seem import build cooper ministri health russia order creat special protocol procedur manag patient pe cteph	D006976;D000086382;D011655	T047;T046;T067
36,286,753	acut decompens heart failur state problem present key aspect manag patient acut decompens heart failur lead improv clinic outcom describ exist problem possibl solut	D006333	T047;T046
36,286,622	explor epigenom dataset chipseek mani aspect life epigenet alter phenotyp without chang sequenc play essenti role biolog function vast number epigenom dataset emerg result advent next generat sequenc annot comparison visual interpret epigenom dataset remain key aspect comput biolog chipseek bioconductor packag perform analys among variabl epigenom dataset fundament function chipseek includ data prepar annot comparison visual explain articl chipseek freeli avail open sourc packag may found https wwwbioconductororgpackageschipseek wiley period llc basic protocol chipseek epigenom dataset prepar basic protocol annot epigenom dataset basic protocol comparison epigenom dataset basic protocol visual annot result basic protocol function analysi epigenom dataset basic protocol genom wide locus specif distribut epigenom dataset basic protocol heatmap metaplot epigenom dataset	D057890;D012984	T090;T170;T091;T073
36,286,610	aryl danc reaction arylbenzoheterol report migrat aryl danc reaction aryl group heterol alcl effici convert c arylheterol c arylheterol depend electron densiti substrat convers c c arylheterol also possibl catalyt zn otf one pot aryl danceacyl bromin arylationaryl danc cascad also demonstr	D003615	T056
36,286,606	multiplex singl nucleus rna sequenc use lipid oligo barcod protocol describ robust pipelin simultan analyz multipl sampl singl nucleus sn rna seq cdna obtain singl sampl label lipid coupl oligonucleotid barcod x genom nuclei mani individu sampl pool togeth simultan process cdna librari construct subsequ dna sequenc previous protocol use lipid coupl oligonucleotid barcod optim analysi sampl consist viabl cell protocol optim analys quick frozen cell sampl protocol ensur effici recoveri nuclei incorpor high sucros buffer solut includ track dye trypan blue nuclei isol protocol also describ procedur remov singl nuclei artifact remov cell debri prior singl nuclear fraction protocol inform use comput tool filter poor label nuclei assign sampl ident use barcod uniqu molecular identifi umi read count percentag comput pipelin applic either cultur primari fresh frozen cell regardless cell type speci overal protocol reduc batch effect experiment cost enhanc sampl comparison wiley period llc basic protocol label cell lipid oligo barcod generat multiplex singl nucleus rna seq librari basic protocol bioinformat deconvolut multiplex snrnaseq librari	D014343;D013395	T123;T121;T130;T109
36,286,602	multicent random doubl blind placebo control crossov trial evalu efficaci safeti zolmitriptan nasal spray acut treatment migrain patient age year open label extens evalu efficaci safeti zolmitriptan nasal spray zns acut treatment migrain headach patient age year	D059085;D008881	T047;T074
36,286,601	digit headach self manag intervent patient primari headach disord systemat review random control trial articl systemat review empir literatur examin efficaci digit headach manag intervent patient primari headach disord	D000073278;D051270	T033;T058;T047
36,286,600	narrat review peripher nerv block manag headach provid overview current avail literatur peripher nerv block manag migrain headach disord adult	D003027;D008881;D020773;D009437	T184;T047
36,286,595	pneumonia subsequ risk dementia evid japan gerontolog evalu studi recent sever studi report pneumonia might increas risk cognit declin dementia due increas frailti	D000073496;D003704;D011014	T184;T050;T033;T047;T046;T048
36,286,593	total synthesi cordycep militari glycan via stereoselect orthogon one pot glycosyl glycosyl strategi cordycep militari glycan potent antioxid activ effici collect synthes synthet approach featur follow stereoselect orthogon one pot glycosyl strategi tran cis glycosid linkag merg reagent modul remot anchimer assist rmraa glucosyl strategi dmf modul glucosyl converg orthogon one pot assembl target tridecasaccharid	D032661	T004
36,286,590	interfer glucos bioavail tumor engin biohybrid potenti target uptak antitumor nanodrug chemotherapi efficaci nanodrug restrict poor tumor target uptak engin biohybrid live materi design ecn hpb construct integr paclitaxel bay bound human serum albumin nanodrug hpb escherichia coli nissl ecn due inher tumor tropism ecn ecn hpb could activ target tumor site competit depriv glucos bacteri respir thus albumin would use altern nutrient sourc tumor metabol signific promot intern hpb tumor cell subsequ bay intern along hpb nanodrug would depress glucos uptak tumor cell via inhibit glucos transport glut togeth declin glucos bioavail tumor cell would activ promot macropinocytosi amp activ protein kinas ampk depend manner result uptak hpb tumor cell boost therapeut outcom paclitaxel	D009369;D004927;D053758	T047;T191;T073
36,286,589	health secur plan develop cameroon nation action plan health secur health secur plan process transform recommend various evalu prioriti action strengthen countri capac emerg prepared use one health approach although world health organ develop mani tool facilit plan process nation action plan health secur naph across various compon seri multisector workshop still need complet process articl report process develop cameroon naph propos innov solut improv process naph develop process conduct may decemb naph framework adapt local context guid process plan matrix use plan activ naph cost tool use facilit cost exercis total joint extern evalu recommend translat activ includ cameroon naph among activ major medium prioriti total cost year naph us almost half budget alloc activ prevent categori third alloc detect categori top cost driver immun nation laboratori system antimicrobi resist naph inform policymak plan activ fund need fast track develop health secur capac run gap fund address resourc map exercis improv overal plan process web base support solut stakehold select menu recommend joint extern evalu develop naph develop improv naph develop process	D007391;D000890	T121;T064
36,286,588	promis emerg nanobiotechnolog vivo applic implic safeti secur nanotechnolog multidisciplinari field base exploit uniqu physicochem properti nanoparticl nps nanoscal materi open new realm possibl biolog research biomed applic develop deploy mrna np vaccin covid exampl may revolution vaccin therapeut howev regulatori ethic framework protect health safeti global communiti environ lag particular nanotechnolog gear toward biolog applic ie bionanotechnolog articl comprehens attempt illustr breadth promis bionanotechnolog develop may present futur safeti secur challeng specif address current advanc streamlin develop engin nps vivo applic provid discuss nano bio interact np vivo deliveri nanoenhanc human perform nanomedicin impact nps human health environ	D000086663;D000086382	T200;T047;T067
36,286,580	light induc iron catalyz trifluoromethyl thiolat alken seri novel trifluoromethyl thiolat alken realiz use visibl light drive forc iron salt catalyst bis trifluoromethyl compound could obtain moder good yield multicompon protocol proceed atom econom way broad substrat scope biolog activ chemic also toler provid desir product suggest catalyt protocol could viabl late stage modif pharmaceut discoveri last flow setup synthesi desir product success appli gram scale indic synthet power reaction industri applic	D000475;D007501	T123;T196;T121;T109
36,286,579	accept implant hiv treatment young children perspect health care provid johannesburg south africa south africa less half children receiv antiretrovir therapi viral suppress adher challeng includ poor palat drug high pill burden subcutan implant offer long act altern daili oral dose regimen may improv outcom children live hiv clwh qualit depth interview conduct health care provid hcps johannesburg south africa interview audio record transcrib data code analyz use nvivo softwar ground theori approach hcps welcom implant option clwh perceiv benefit includ fewer clinic visit improv adher normal live clwh concern includ pain insert remov potenti stigmat caregiv like reject biodegrad implant singl small non transpar rod flexibl prefer particip hcp train earli outreach mitig potenti misinform implant caregiv fear biodegrad implant emphas engag caregiv clwh requir ongo	D015658	T047
36,286,578	episod use pre exposur prophylaxi among young cisgend women siaya counti kenya concept season risk promot use pre exposur prophylaxi prep period hiv risk prep guidelin align daili use women vagin sex risk period daili use day last potenti exposur recommend howev start season risk guidelin vari time protect unknown remain pharmacolog research prep protect popul iter research prep persist use photovoic depth interview identifi ineffect pattern prep use base current guidelin routin episod use among young cisgend women ycw siaya counti kenya group n particip mix group n particip photovoic activ ycw take prep femal peer particip explain ycw associ hiv risk sexual behavior male partner frequent travel home prep consid unnecessari partner away perceiv risk ycw start prep around day partner return heighten risk percept among ycw interview n near partner travel week month time one third women report stop prep partner absenc start soon immedi upon partner arriv home addit research critic need better inform prep guidelin decis adolesc girl young women make use prep base risk context interim counsel current dose guidanc stop start prep within season risk need	D065129;D019380;D015658	T061;T121;T047
36,286,577	factor associ post exposur prophylaxi awar among latino sexual minor men south florida despit efficaci biomed hiv prevent tool post exposur prophylaxi pep pre exposur prophylaxi prep insuffici scale dissemin especi among margin subgroup face substanti hiv dispar given minim literatur avail pep among latino sexual minor men lsmm cross section secondari analysi explor factor associ pep awar among group lsmm live south florida us hiv epicent parent studi examin pattern engag prep behavior health treatment servic among lsmm n current secondari analysi n identifi factor associ pep awar use three method stochast search variabl select participatori data scienc literatur review model use linear regress particip report littl awar pep initi studi simpl linear regress model suggest higher prep knowledg b se p hiv knowledg b se p prep self efficaci b se p high perceiv communiti norm hiv test b se p associ lsmm greater pep awar ident affirm associ less pep awar b se p result suggest util three prong variabl select approach address gap pep awar use among lsmm live us hiv epicent support end hiv epidem goal	D015658;D065129;D000072339	T061;T047;T098
36,286,576	intens puls light therapi inhibit meibomian gland inflamm untarget metabolom analysi meibomian gland secret object assess inhibitori effect intens puls light ipl meibomian gland mg inflamm background ipl treatment effect dri eye diseas ded caus meibomian gland dysfunct mgd howev anti inflammatori regener stimul effect ipl mgd remain unclear moreov studi inflammatori metabolit mg secret lack method six patient ded administ two ipl treatment ocular surfac diseas index osdi questionnair use assess ded mgd sign includ degre obstruct secret atrophi mg tear film break time tbut assess treatment determin ipl treatment induc chang metabolit liquid chromatographi tandem mass spectrometri lc msms use analyz mg secret result data gather first treatment time week second treatment time b averag osdi score show signific decreas time b measur respect besid statist signific differ observ mg sign treatment degre obstruct improv secret becam thinner tbut signific increas normal rang lc msms led identif differenti metabolit upregul eg estradiol coenzym q azela acid downregul eg prostaglandin hydroxyeicosatetraeno acid arachidon acid kyoto encyclopedia gene genom pathway enrich analysi show differenti metabolit involv steroid hormon biosynthesi conclus periorbit ipl treatment improv chronic inflamm mg promot normal secret steroid hormon biosynthet pathway may activ particip anti inflammatori effect	D062325;D000080343	T061;T047
36,286,575	q switch nm nd yag laser rejuven photoag skin rat downregul mir b p background q switch nm nd yag laser qsnyl effici rejuven photoag skin microrna mirna particip process object studi aim explor effect qsnyl mir b p tgf beta receptor ii tgfbr smad photoag skin rat method relationship mir b p tgfbr hacat cell detect real time pcr western blot skin photoag model establish wistar rat use ultraviolet uv radiat uvr dermoscopi hematoxylin eosin stain sirius red stain hydroxyprolin content use observ effect uvr rat skin qsnyl use skin rejuven express cola tgfb tgfbr smad smad smad detect real time pcr andor western blot result tgfbr specif target mir b p skin hacat cell photoag skin rat qsnyl treatment upregul cola tgfbr downregul smad mir b p conclus show first time qsnyl treatment rejuven photoag rat skin regul tgfbr smad downregul mir b p assist process target upregul tgfbr	D053844;D015595;D035683	T123;T073;T042;T033;T114;T074
36,286,574	custom photobiomodul modul pain alter thermographi pattern patient knee osteoarthr random doubl blind pilot studi background photobiomodul therapi pbmt modul wide varieti biolog process lead anti inflammatori analges effect understand mechan under therapeut effect pbmt remain challeng due vari outcom observ wavelength dosag site applic research group dedic close attent custom individu dosimetri pbmt protocol preliminari data show use individu treatment could solv contradictori result report previous studi base literatur preliminari data light absorpt goal present pilot determin whether individu dosimetri feasibl method assist osteoarthr oa pain control method parallel two arm control pilot studi aim assess whether person pbmt effect treatment pain chronic knee oa thirti one patient random alloc treatment placebo group sham irradi treatment procedur perform twice week week pbmt appli use nm continu wave total j session individu dosimetri chosen base patient bodi mass index skin color qualiti life qol questionnair serumurin analys perform treatment examin particip blind group alloc result pain score reduc signific th th th session remain lower week posttherapi treatment group compar placebo group moreov treatment group result improv qol questionnair score dopamin level microcircul conclus present result provid initi evid custom photobiomodul pbm reduc pain level short medium term patient symptomat knee oa compar placebo group furthermor provid evid custom pbm abl improv qol patient	D020370	T047
36,286,571	melanoma investig primari treatment melanoma relat common diagnosi primari specialist health servic ongo research new evid base mean recommend investig treatment continu chang lead uncertainti among doctor treat patient group regular clinic review give summari latest recommend primarili aim general practition dermatologist doctor local hospit	D008545;D010820;D012878	T191;T097
36,286,565	woman delus hallucin dyston eye movement woman earli rare neurogenet syndrom admit psychiatr depart suspicion psychot disord cours ill patient suffer episod involuntari eye movement behaviour chang psychot symptom difficult treat	D011618;D004421	T184;T048
36,286,559	breastfeed treatment multipl sclerosi monoclon antibodi therapi effect multipl sclerosi small amount antibodi transfer breast milk even though approv product descript advis breastfeed medicin treatment sever effect ms drug compat breastfeed	D001942;D009103	T055;T058;T040;T047
36,286,556	histopatholog reassess melanoma melanocyt skin lesion excis histopatholog assess melanoma melanocyt skin lesion difficult vari pathologist	D004416;D008545;D012878;D009506	T191
36,286,547	increas detect carbapenemas produc enterobacteral bacteria latin america caribbean covid pandem countri latin america caribbean report clinic emerg carbapenemas produc enterobacteral previous character local increas preval carbapenemas previous detect co product multipl carbapenemas isol increas like fuel chang relat covid pandem includ empir antibiot use potenti covid relat bacteri infect healthcar limit result rapid rise covid case strengthen antimicrobi resist surveil epidemiolog research infect prevent control program antimicrobi stewardship clinic set help prevent emerg transmiss carbapenemas produc enterobacteral	D000086382	T047;T067
36,286,543	acetylpyridin tissu patern bchi derivat enabl high coverag lipid cc locat resolv ms imag biolog tissu unsatur lipid contain singl carbon carbon doubl bond cc within tissu close associ various type diseas mass spectrometri imag msi use studi spatial distribut lipid cc locat isom tissu section howev comprehens character lipid cc locat isom use msi remain challeng herein establish tissu charg switch patern bchi pb derivat method use acetylpyridin ap reaction reagent use detect assign cc locat glycerophospholipid gpls well neutral lipid fatti acid fas experiment workflow use matrix assist laser desorptionion maldi msi high coverag mono poli unsatur cc locat isom among various lipid class includ fa phosphatidylcholin pc sulfatid shexcer distinct region mous brain kidney visual use maldi msms imag method also appli map spatial distribut lipid cc locat isom alzheim diseas ad mice model first time provid new tool studi relationship distribut lipid structur divers neurodegen diseas	D053719;D020404	T063;T109

36,286,961

antibodi phosphatidylserineprothrombin complex diagnosi antiphospholipid syndrom determin signific antibodi phosphatidylserineprothrombin complex apspt patient system lupus erythematosus sle antiphospholipid syndrom ap

D016736;D008180;D013927

T047;T046

36,286,960

burden progress psoriat arthriti russian regist data psoriat arthriti psa complex immun mediat diseas third patient psoriasi pso inflammatori lesion musculoskelet system peripher joint axial structur extra articular manifest dactyl enthes nail pso uveiti inflammatori bowel diseas

D015535;D011565

T047

36,286,959

success psychopharmacotherapi anxieti depress disord improv function limit patient rheumatoid arthriti compar chang function limit patient rheumatoid arthriti ra comorbid anxieti depress disord add treat convent synthet diseas modifi antirheumat drug csdmard alon combin biolog dmard bdmard andor psychopharmacotherapi ppt determin predictor haq treatment respons

D001172;D018501;D001688;D003866

T121;T047;T123;T048

36,286,958

evalu associ polymorph cypc gene efficaci safeti ketorolac patient postop pain syndrom evalu possibl associ cypc gene polymorph clinic efficaci safeti ketorolac relat postop pain

D020910;D010149

T121;T047;T184;T109

36,286,957

janus kinas inhibitor immunoinflammatori rheumat diseas despit great advanc diagnosi treatment immunoinflammatori rheumat diseas led signific improv prognosi mani patient fundament medic problem patholog restor qualiti life reduct mortal popul level far resolv serv stimulus studi new approach pharmacotherapi ivrd one associ use low molecular weight chemic synthes drug inhibit intracellular signal molecul janus kinas modern advanc regard use janus kinas inhibitor treatment immunoinflammatori rheumat diseas covid consid

D000075242;D000086382;D012216;D000076742

T121;T047;T067

36,286,954

format cardiolog ussr call founder xx centuri special clinic area gradual emerg general bodi intern medicin among cardiolog becam one first literatur yet explicit consid question consid founder russian cardiolog data suggest dd pletnev gf lang nd strazhesco vf zelenin al myasnikov ei chazov exhaust nomin composit founder cardiolog ussr

D002309

T091

36,286,953

featur intestin condit patient new coronavirus infect covid infect may present gastrointestin lesion patient one target organ sar cov virus intestin pathogenesi intestin damag new coronavirus infect remain unclear requir depth studi possibl mechan includ direct cytotox effect virus persist reduct butyr produc bacteria side effect drug clostridioid difficil infect microvascular thrombosi immun mediat inflammatori reaction intestin common symptom intestin damag coronavirus infect acut phase post covid period diarrhea impact mani aggress factor intestin form long term function disord caus onset organ diseas treatment aim possibl caus intestin damag clostridioid difficil well reduc inflamm restor intestin permeabl cytoprotect mucos cell replenish butyr acid defici choos therapi intestin disord prefer given drug pleiotrop effect order influenc various possibl pathogenet mechan

D000086402;D000086382

T005;T067;T047

36,286,952

problem associ effect pharmacotherapi elder patient geriatr review world older popul grow dramat time ensur appropri high standard live elder reduc morbid disabl geriatr patient one main object modern healthcar system howev chang associ bodi age necessit applic novel approach correct pharmacotherapi usag special dosag form medicin product provid appropri therapeut effect facilit use present review consid sever featur pharmacotherapi geriatr patient

D005853

T090;T091

36,286,951

stress induc arteri hypertens stress consid one factor associ develop mani diseas includ cardiovascular system histori studi stress risk factor hypertens began first half th centuri continu introduct hour blood pressur monitor abpm clinic practic turn normotens stabl hypertens latent hypertens mask clinic bp within normal rang arteri hypertens record accord abpm andor self monitor bp white coat hypertens increas bp visit doctor normal valu blood pressur accord abpm self monitor bp current variant latent hypertens classifi stress induc arteri hypertens sever model propos studi stress two common clinic studi karasek model base imbal job demand job decis latitud siegrist model base imbal effort reward studi attempt made link increas bp paramet stress respons exampl hormon level genet predisposit review discuss signific studi stress induc arteri hypertens publish date

D006973;D059466

T047

36,286,950

rehabilit patient chronic thromboembol pulmonari hypertens patient pulmonari hypertens ph recommend physic rehabilit long time fact physic activ discourag nowaday posit regard exercis patient ph chang studi shown safeti effect exercis patient studi publish date rehabilit patient ph assess effect exercis toler review provid overview publish studi conclus effect rehabilit patient chronic thromboembol hypertens complex therapi use medic surgic method treatment rehabilit inclus rehabilit complex treatment allow achiev patient highest possibl toler physic activ increas function class qualiti life restor work capac

D006976;D011655;D000800

T061;T047;T046

36,286,949

erdheim chester diseas cardiac involv case report erdheimchest diseas ecd rare non langerhan histiocytosi multisystem inflammatori infiltr consist monocytesmacrophag reactiv microenviron fibrot field cardiovascular involv one frequent manifest ecd lead life threat complic articl report clinic case ecd cardiac involv young patient

D031249

T047

36,286,948

pathomorpholog clinic characterist blastic plasmocytoid dendrit cell neoplasm case report paper reveal case date blastic plasmacytoid dendrit cell neoplasm present inform demonstr morpholog immunohistochem data clinic manifest

D012878;D009196;D019337

T191

36,286,947

asept nasal septal abscess patient ulcer coliti two case report case report ulcer coliti uc may associ differ extra intestin manifest eim often difficult diagnos treat may complic cours diseas eim multidisciplinari problem encount doctor various special howev mani incid eim patient uc remain unknown coexist uc asept nasal abscess ana uncommon describ two case ana young femal patient uc ana run parallel intestin diseas activ led necrosi septal cartilag moreov pyoderma gangrenosum describ one asept abscess syndrom kept mind microbi factor identifi diagnosi clear patient improv appropri antibacteri therapi ana present rare complic uc

D003093;D017511;D012141

T047

36,286,946

peculiar hemostasi patient covid analysi dynam differ stage clot format lysi patient differ covid sever

D000086382;D013927

T047;T046;T067

36,286,945

new opportun prevent anti inflammatori therapi manag patient moder sever covid specif featur new coronavirus infect covid high risk hyperinflammatori respons cytokin storm develop under pathogenesi sever life threaten condit determin diseas outcom pathophysiolog featur covid justifi search effect drug capabl control hyperinflammatori respons

D000893;D000086382

T121;T047;T067

36,286,944

data russian sever asthma registri rsar creation russian regist patient sever asthma obtain data popul characterist patient sever asthma sa preval sa phenotyp treatment outcom degre diseas control

D001249;D001688;D018927

T123;T047;T121

36,286,943

pregnanc paroxysm nocturn hemoglobinuria surviv life pregnanc paroxysm nocturn hemoglobinuria pnh patient histor high risk situat combin chronic complement mediat hemolysi caus diseas physiolog activ complement system pregnanc signific worsen prognosi life long time effect method pnh treatment pregnanc patient seem extrem riski signific increas risk life threaten complic advent target therapi eculizumab turn prognosi diseas upsid patient began surviv also live compar healthi peopl compar analysi cours outcom pregnanc patient pnh treat eculizumab patient without target therapi carri

D006457

T047

36,286,942

pharmacoeconom analysi use fix combin budesonideformoterol patient asthma health care system russian feder evalu budgetari impact use budesonid formoterol symbicort turbuhal mainten therapi real clinic practic compar standard therapi asthma vari sever mild asthma demand salbutamol moder sever asthma drug salmeterol fluticason salbutamol demand

D000069502;D001249

T121;T047;T109

36,286,941

preval clinic associ iron defici patient decompens heart failur depend diagnost criteria use iron defici compar frequenc iron defici id patient decompens heart failur hf defin intern guidelin criterion ferritin ngml ferritin ngml tsat criterion bone marrow biopsi criterion tsat serum iron moll criterion b evalu effect id diagnos basi differ id criteria nt pro bnp sst crp level new york heart associ nyha function class fc distribut group id without id

D000090463;D006333

T047;T046

36,286,940

withdraw syndrom tyrosin kinas inhibitor discontinu patient chronic myeloid leukemia withdraw syndrom ws musculoskelet pain discontinu tyrosin kinas inhibitor tki patient chronic myeloid leukemia cml describ treatment free remiss tfr studi pathophysiolog mechan predispos factor ws well establish

D059352;D015464

T033;T191

36,286,939

multipl myeloma respons treatment surviv patient accord interim analysi russian observ retrospect prospect multicent cohort studi multispect primari object interim analysi multispect studi evalu short term efficaci treatment long term outcom cohort primari pretreat patient multipl myeloma mm receiv treatment actual clinic practic various region russian feder secondari object descript main characterist patient analysi common use therapi regimen st later line sequenc chang evalu respons therapi addit object includ evalu effect new covid coronavirus infect cours mm patient

D009101;D000086382;D018380

T061;T047;T191;T067

36,286,938

ospit outcom coronari arteri bypass graft patient coronari heart diseas previous percutan coronari intervent evalu frequenc hospit cardiovascular event group patient stabl angina underw percutan coronari intervent pci stent arteri coronari bypass surgeri previous myocardi revascular

D062645;D003324;D060050;D009203

T061;T047

36,286,937

combin use grace ac risk score comorbid indic increas effect hospit mortal risk assess patient acut coronari syndrom assess possibl use comorbid indic togeth grace global registri acut coronari event scale assess risk hospit mortal acut coronari syndrom ac

D054058;D062645

T061;T047

36,286,936

chronic kidney diseas outpati arteri hypertens clinic characterist treatment efficaci accord nation registri im investig clinic characterist qualiti treatment accord nation guidelin patient arteri hypertens ah chronic kidney diseas observ primari health care

D003924;D051436;D006973

T047

36,286,935

biochem marker thrombot complic acut period ischem stroke studi profil biochem marker hemostasi system clarifi role relationship pathogenesi develop thrombot complic tc ischem stroke associ assess possibl diagnost applic

D000083242;D000933;D013927

T121;T047;T046

36,286,934

se differ treatment acut coronari syndrom patient data feder registri acut coronari syndrom manag patient acut coronari syndrom ac usual univers regardless gender age ethnic often practic gender age influenc medic decis patient receiv proper medic care medic care patient ac analyz gender accord feder regist ac data

D054058;D062645

T061;T047

36,286,933

chronic thromboembol pulmonari hypertens pathogenesi choic treatment tactic present data pathogenesi chronic thromboembol pulmonari hypertens cteph serv rational approach choic treatment cteph usual begin persist obstruct larg andor medium pulmonari arteri organ thrombi impair lysi thrombi may associ abnorm fibrinolysi hematolog autoimmun diseas molecular process under lesion small vessel fulli understand degre small vessel diseas signific impact sever cteph postop outcom cteph treatment evolv develop three direct pulmonari endarterectomi balloon angioplasti pulmonari arteri use specif therapi use pulmonari arteri hypertens paper demonstr possibl multimod approach treatment categori patient

D006976;D011655;D000800

T061;T047;T046

36,286,931

hypnotherapi increas well emot well broad term refer happi posit social relationship life balanc pursuit posit goal emot well shown reduc risk death near cohen et al lead articl na et al explor issu report pilot studi hypnot relax therapi well hrt wb find demonstr particip achiev high level well flourish addit innov studi sever articl includ increas access scale measur hypnotiz french apelian russian kvitchasti spanish muiz et al kaso et al explor role hypnotiz regard skin conduct orient respons scr respons differ type suggest final cordi rasch explor role hypnotiz accur percept sleep find suggest sleep depth may associ slow wave sleep interocept abil accur perceiv sleep depth depend hypnotiz togeth studi identifi new applic clinic hypnosi increas avail scale measur hypnotiz across cultur understand hypnotiz

D006990

T061

36,286,858

histori special clinic intern diseas role ss zimnitski kazan format nephrolog ussr russian nephrolog like clinic disciplin pass two stage histor develop first stage becam isol import area scientif research within framework soviet clinic intern diseas second stage becam independ scientif educ clinic disciplin medic specialti articl show role kazan internist ss zimnitski one founder nephrolog ussr first stage format one leader function direct soviet clinic medicin

D009398;D015510

T091

36,286,857

kidney damag caus lead exposur histor aspect articl present histor analysi public devot lead intox kidney damag develop contact lead shown one manifest occup intox metal toxic nephropathi

D007674;D007855;D009784;D016273

T047;T037

36,286,856

modern view complement system role membran nephropathi membran nephropathi mn immun mediat glomerular diseas common caus adult nephrot syndrom mn proteinuria develop podocyt damag due complement system activ respons subepitheli deposit immun complex contain various auto exogen antigen membran attack complex mac termin product complement pathway activ classic lectin altern play lead role complement mediat podocyt damag thus far main pathway complement activ lead format mac mn establish review highlight current evid various complement pathway activ develop mn well recent establish new molecular mechan complement mediat podocyt damag

D015433

T047

36,286,855

diagnost treatment difficulti kidney damag patient general sarcoidosi covid case report present clinic observ reflect difficulti differenti diagnosi progress kidney damag patient sarcoidosi undergon new coronavirus infect differenti circl includ interstiti nephriti exacerb under diseas acut drug induc kidney injuri acut glomerulonephr nephrobiopsi confirm diagnosi acut sarcoid tubulointerstiti nephriti acut tubular necrosi time administr corticosteroid led control sarcoidosi process restor kidney function

D000086382;D009395;D012507

T047;T067

36,286,854

impact kidney biopsi manag patient rheumatolog depart retrospect studi kidney involv common manifest system autoimmun rheumat diseas kidney biopsi gold standard diagnosi kidney diseas howev method yet becom standard care rheumatolog practic

D012219;D008180

T047;T091

36,286,853

soy protein part low protein diet new direct cardio nephroprotect patient b stage chronic kidney diseas prospect random control clinic studi establish use low protein diet lpd combin ketoanalogu ka essenti amino acid contribut cardio nephroprotect chronic kidney diseas ckd moreov shown replac part anim protein soy protein sp diet contribut pronounc nephro cardioprotect ckd howev data avail literatur main repres experiment studi

D018753;D051436

T061;T047

36,286,852

new opportun neuroprotect therapi patient acut earli recoveri period ischem stroke evalu efficaci safeti brainmax comparison ethylmethylhydroxypyridin succin trimethylhydrazinium propion patient ischem stroke acut earli recoveri period

D002545;D000083242;D020521

T047;T046

36,286,851

risk factor kidney injuri patient covid determin incid risk factor acut kidney injuri aki russian cohort patient covid

D000086382;D058186;D051436

T047;T037;T067

36,286,850

evalu hemostasi disord use thrombodynam test patient chronic glomerulonephr nephrot syndrom nephrot syndrom ns accompani risk thrombot complic due hypercoagul routin laboratori test sensit enough detect disord therefor use integr coagul test includ new thrombodynam test tt patient ns high relev

D009404;D019851;D013927;D005921

T047;T046

36,286,849

clinic signific serum level osteoproteherin sclerostin assess vascular calcif chronic kidney diseas stage clarifi mechan effect osteoprotegerin opg sclerostin vascular calcif state cardiovascular system chronic kidney diseas ckd

D061205;D051436

T047

36,286,848

urinari biomark kidney injuri patient treat anti vegf drug antiangiogen drug wide use oncolog practic aim inhibit angiogenesi despit high antitumor efficaci use may limit nephrotox therefor search earli biomark kidney damag remain relev preserv favor safeti profil therapi

D058186;D007674;D051437

T047;T037

36,286,847

remiss progress c glomerulopathi analyz outcom c glomerulopathi c gp determin associ factor

D015432;D007674

T047

36,286,846

lupus nephriti xxi centuri lupus nephriti ln common organ lesion system lupus erythematosus sle develop patient due immunosuppress therapi surviv patient sle increas signific past year proport sever kidney damag death structur decreas howev ln relaps complic immunosuppress acceler atherogenesi concomit diseas lead accumul organ damag increas risk death articl consider place kidney damag sle risk factor ln develop main renal histopatholog chang identifi number issu need address optim treatment improv ln long term outcom includ revis pathogenet therapi regimen restrict glucocorticosteroid prescrib drug steroid spare activ integr new drug ln treatment wider use modern nephroprotect capabl

D008181;D008180;D007676

T047

36,286,844

assess antitumor antiprolif efficaci detect protein protein interact cancer cell tumor spheroid compar two dimension cell cultur spheroid consid suitabl vitro model drug discoveri research studi drug activ base differ cell cultur procedur describ procedur use obtain tumor spheroid hang drop ultra low attach plate method analyz antiprolif antitumor efficaci differ chemotherapeut agent includ peptidomimet appli method breast lung cancer cell line bt mcf calu also describ proxim ligat assay cell spheroid model detect protein protein interact egfr wiley period llc basic protocol growth spheroid use hang drop method basic protocol growth spheroid use ultra low attach plate support protocol cell viabil assay tumor spheroid support protocol antiprolif antitumor studi tumor spheroid support protocol proxim ligat assay cell deriv spheroid

D057786;D008175

T121;T191

36,286,813

page histori therapeut school central institut improv doctor russian medic academi continu profession educ therapeut scientif pedagog school form central institut advanc train physician cardiolog school prof dmitri pletnev school clinic hematolog emerg care prof alexand n kryukov school dietet gastroenterolog prof manuel pevzner school hematolog prof joseph kassirski mark th anniversari birth outstand therapist academician ussr academi medic scienc major general medic servic prof miron vovsi along fact ms vovsi belong scientif pedagog school cardiolog prof dd pletnev manag creat ms vovsi one creator modern militari field therapi expand understand pathogenesi nephriti pneumonia coronari heart diseas hypertens heart failur introduc new method diagnos treat therapeut patholog lost relev today

D004517;D010820

T065;T097

36,286,812

practic guidelin diagnosi treatment transthyretin amyloid cardiomyopathi attr cm transthyretin cardiac amyloidosi paper summar data updat intern protocol guidelin diagnosi transthyretin amyloid cardiomyopathi attr cm invas non invas diagnosi techniqu combin briefli review evidentiari foundat diagnost option tool analyz paper describ custom algorithm sequenti diagnosi differenti diagnosi patient suspect attr cm allow combin clinic sign diagnost find along awar primari care provid red flag diseas visual criteria well provid inform patient possibl perform therapi attr amyloidosi risk delay diagnosi propos algorithm enabl time patient rout prescrib specif treatment

D000686;D009202

T047

36,286,811

risk develop cardiovascular diseas bipolar disord biolog factor therapi bipolar disord bd one common mental disord character altern episod maniahypomania depress well possibl develop mix condit correct time diagnosi bd import due presenc high suicid risk high predisposit develop cardiovascular diseas cvd risk cvd higher mental disord

D001714;D002318;D019161

T121;T047;T109;T048

36,286,810

manag iron defici chronic heart failur iron defici frequent patient chronic heart failur chf preval frequenc vari depend studi group presenc iron defici limit erythropoiesi lead develop anemia time patient chf regardless gender race left ventricular eject fraction lvef observ studi demonstr higher preval iron defici women patient higher nyha new york heart associ function class decreas lvef increas brain natriuret peptid nt probnp increas high sensit c reactiv protein iron defici anemia patient chf independ associ decreas exercis capac hospit chf increas overal mortal mortal cardiovascular diseas clinic signific iron defici requir need diagnos iron metabol patient chf current guidelin diagnosi treatment chf indic need determin level ferritin satur transferrin patient suspect diagnosi heart failur use oral iron therapi patient chf demonstr low efficaci correct condit accord clinic trial time use intraven iron therapi safe improv symptom exercis capac qualiti life patient heart failur reduc eject fraction iron defici shown intern placebo control trial meta analys use iron carboxymaltos improv chf symptom exercis capac qualiti life patient chf lvef intraven iron therapi also shown reduc readmiss chf patient lvef recent hospit worsen chf

D007501;D000090463

T123;T196;T121;T047

36,286,809

sglt inhibitor acut decompens heart failur know current worldwid preval heart failur grow combin cardiovascular condit determin poor prognosi patient furthermor acut decompens heart failur associ low surviv rate most caus target organ damag effect earli administr sglt inhibitor renal function patient acut decompens heart failur studi determin possibl improv respons treatment well partial complet recoveri renal function goal review synthes current avail evid use sglt inhibitor patient acut decompens heart failur systemat search studi publish analysi carri follow databas web scienc scopus pubmedmedlin

D000077203;D003924;D006333

T121;T047;T046;T109

36,286,808

non compact right ventricular myocardium diagnost clinic featur review non compact right ventricular myocardium rare type cardiomyopathi usual result arrest myocardi develop embryogenesi diseas character excess promin trabecul deep inter trabecular recess ventricular wall might compon biventricular non compact cardiomyopathi isol form articl present review literatur clinic radiat diagnost non compact right ventricular myocardium present issu differenti diagnosi

D004452;D009202

T060;T047

36,286,807

role cardiac magnet reson imag defin prognosi patient acut st segment elev myocardi infarct part assess diseas prognosi current incid congest heart failur st segment elev myocardi infarct stemi tend increas reperfus therapi still effect method reduc infarct size therefor high unmet need novel cardioprotect treatment would improv outcom patient recent advanc cardiovascular magnet reson cmr method enabl identif certain new infarct characterist associ develop heart failur sudden cardiac death characterist help identifi new group high risk patient use target novel cardioprotect treatment part review summar novel cmr base characterist myocardi infarct role prognost stratif stemi patient

D000072657;D062645;D009203;D006333

T061;T047;T046

36,286,806

chronic inflammatori demyelin polyneuropathi acut onset clinic case chronic inflammatori demyelin polyneuropathi cidp heterogen treatabl dysimmun neuropathi varieti clinic form cours diseas challeng proper diagnosi earli treatment quarter case cidp start acut mimick guillainbarr syndrom earli diagnosi especi import regard differ treatment prognosi condit articl present clinic case acut onset cidp detail analysi differenti diagnosi acut chronic immun mediat neuropathi

D020277;D020275

T047

36,286,805

rare clinic case patient pulmonari hypertens associ hereditari hemorrhag telangiectasia case report articl describ rare clinic case patient pulmonari hypertens associ hereditari hemorrhag telangiectasia discuss issu treatment choic patient present clinic case interest pulmonari hypertens initi reveal hereditari natur confirm oslerweberrendu diseas diagnos

D013683;D006976

T047;T046

36,286,804

myocardi scintigraphi tc pyrophosph diagnosi cardiac amyloidosi place diagnost algorithm featur implement interpret studi articl summar current experi nuclear medicin depart chazov nation medic research center cardiolog implement myocardium scintigraphi mtc pyrophosph differenti diagnosi type cardiac amyloidosi caus fals posit equivoc non diagnost result analyz possibl way elimin mistak includ modifi protocol planar tomograph research optim whole diagnost algorithm amyloidosi heart discuss

D055414;D009202;D000686

T060;T047

36,286,803

problem opportun improv diagnosi asthma chronic obstruct pulmonari diseas russia resolut advisori board asthma chronic obstruct pulmonari diseas remain major problem medicin still need improv level qualiti diagnosi diseas primari care physician general practition therapist involv wide activ process simplifi diagnosi special questionnair develop use real clinic practic approach bring statist data closer true preval diseas improv qualiti treatment

D029424;D001249

T047

36,286,802

possibl improv treatment chronic heart failur accord result multicent observ studi byheart studi efficaci safeti exogen phosphocreatin ef patient chronic heart failur chf

D011788;D006333

T078;T047;T046

36,286,801

zonulin fabp marker enterocyt damag celiac diseas evalu level serum fabp fatti acid bind protein protein bind fatti acid fecal zonulin marker permeabl mucous membran small intestin celiac patient

D002446

T047

36,286,800

predict valu qrs complex durat patient chronic heart failur atrial fibril retrospect studi studi featur clinic cours prognosi patient chronic heart failur low eject fraction hfref atrial fibril af depend width qrs complex

D006333;D001281

T047;T046

36,286,799

organ pneumonia pulmonari manifest post covid syndrom featur diagnosi treatment treatment patient long term persist symptom covid urgent problem clinician around world one signific manifest post covid syndrom organ pneumonia usual treat corticosteroid paper present clinic case typic cours post covid organ pneumonia patient without previous lung diseas risk factor diagnost method treatment option group patient also discuss

D000086382;D011014

T047;T050;T067

36,286,798

proinflammatori laboratori predictor pneumonia ischem stroke patient prospect studi bacteri pneumonia frequent complic ischem stroke hospit stage search prognost laboratori marker pneumonia remain urgent task allow individu approach treatment rehabilit patient

D000083242;D011014;D054497;D020521

T047;T116;T050;T126

36,286,797

new approach diagnosi lung lesion patient covid lung ultrasound protocol versus ct scan develop protocol ultrasound diagnost covid pneumonia assess diagnost capabl method comparison comput tomographi ct

D000086382

T047;T067

36,286,796

relationship level l preval atherosclerosi among young patient hyperlipoproteinemia independ caus risk factor atherosclerot cardiovascular diseas ascvd correl lipoprotein lp inflamm vessel wall activ studi past year c reactiv protein crp play import role ascvd

D050197;D019161;D006951

T121;T047;T046;T109

36,286,795

transthyretin amyloid cardiomyopathi featur histolog diagnosi studi design compar effici specif featur transthyretin amyloid stain differ histolog dye thus assess suitabl diagnost purpos

D028227;D009202

T047

36,286,794

prognost signific equival densiti calcium deposit coronari arteri men osteopen syndrom prior coronari arteri bypass graft prospect studi determin clinic prognost valu equival densiti calcium deposit edcd coronari arteri patient stabl coronari heart diseas chd concomit osteopen syndrom os coronari arteri bypass graft cabg base five year follow

D002118;D003324

T123;T196;T121;T047

36,286,793

molecular cardiolog decod genet natur mechan diseas develop introduct clinic recent decad advanc molecular biolog led chang understand inherit mechan develop cardiolog diseas predomin genet origin hypertroph dilat cardiomyopathi famili hypercholesterolemia etc knowledg made possibl develop fundament new drug intervent program detect cardiac diseas predomin genet origin creat includ genet counsel test compet area becom necessari part cardiologist job

D002311;D002309

T047;T091

36,286,765

histori vectorcardiographi past present futur vector concept analysi electr signal heart began use dawn develop electrocardiolog sever decad vectorcardiographi develop parallel electrocardiographi reach peak period cool experienc resurg sinc earli becam possibl mathemat synthes vectorcardiogram vcg digit electrocardiogram lead vcg reflect phenomena electrocardiographi allow calcul visual number three dimension characterist electr signal heart articl describ main mileston develop vcg histori intern cooper area contribut domest scientist field scienc modern promis area research relat vector concept analysi electr signal heart briefli reflect

D014672;D004562

T060;T074

36,286,764

heart failur obes obes independ predictor cardiovascular diseas cvd includ heart failur hf nevertheless numer studi shown patient cvd overweight slight obes better short term moder prognosi thinner patient cvd phenomenon call obes paradox understand obes paradox import patient hf given high preval obes patient hf articl present overview clinic studi devot studi obes risk factor hf pathogenesi hf obes highlight issu obes paradox treatment obes categori patient

D006333;D002318

T047;T046

36,286,763

patent foramen oval caus recurr embol stroke case report clinic case young patient recurr ischem stroke present problem diagnost embol stroke discuss set algorithm identifi patient patent foramen oval probabl caus embol stroke detail consider imag diagnost method possibl includ hypothesi probabl sourc cardioembol patent foramen oval present recommend secondari prevent recurr ischem stroke associ patent foramen oval provid also consid issu antithrombot treatment

D054092;D000083262;D020521

T019;T047

36,286,762

preval combin function dyspepsia irrit bowel syndrom meta analysi studi use rome iii iv criteria systemat data preval combin function dyspepsia fd irrit bowel syndrom ib use rome iiiiv criteria

D004415;D043183;D005767

T184;T047

36,286,761

mechan circulatori support refractori cardiogen shock retrospect regist studi cardiogen shock cs one main caus death patient acut myocardi infarct ami mortal cs remain high despit introduct myocardi revascular use modern medic use mechan circulatori support mcs promis could reduc mortal patient ami cs

D012770;D009203

T047;T046

36,286,760

impact anxieti disord adher anticoagul therapi patient atrial fibril evalu impact anxieti disord adher anticoagul therapi act patient atrial fibril af

D001281

T047;T046

36,286,759

effect cardiac contractil modul patient chronic heart failur atrial fibril result month follow evalu efficaci safeti effect prognosi cardiac contractil modul ccm patient chronic heart failur chf reduc left ventricular eject fraction atrial fibril compar group optim drug therapi odt month follow

D001281;D006333

T047;T046

36,286,758

ectop obes patient without manifest cardiovascular diseas regul frequenc clinic characterist determin frequenc distribut characterist ectop obes patient without manifest cardiovascular diseas

D002318;D006973

T047

36,286,757

featur vectorcardiogram patient hypertens complic chronic heart failur reduc left ventricl eject fraction explor featur vectorcardiogram vcg patient essenti hypertens complic chronic heart failur reduc left ventricular eject fraction chfrlvef

D006333;D001281;D006973

T047;T046

36,286,756

remot electrocardiogram telemonitor endovascular intervent coronari arteri evalu effect new system telemetr electrocardiogram ecg monitor patient endovascular intervent ei coronari arteri ca

D003331;D004562

T060;T023;T074

36,286,755

atorvastatin effect prevent contrast induc acut kidney injuri comput tomographi contrast media assess role atorvastatin frequenc contrast induc acut kidney injuri ci aki patient cardiovascular diseas cvd undergo comput tomographi ct intraven contrast media

D019161;D002318;D058186

T121;T047;T037;T109

36,286,754

guid light diagnosi chronic thromboembol pulmonari hypertens flow patient pulmonari embol decemb expert council held determin posit expert differ specialti regard reason low level diagnosi chronic thromboembol pulmonari hypertens cteph real clinic practic pandem new coronavirus infect possibl way improv detect patient pulmonari embol pe histori reason low level diagnosi cteph insuffici level knowledg specialist especi primari care physician lack clear regulatori document expert center manag categori patient primari diagnosi cteph pandem strengthen widespread use telemedicin consult primari care physician specialist expert center maxim role echocardiographi comput tomographi ct differenti diagnost tool dyspnea particular patient covid increas detect rate cteph diagnost vigil requir patient risk factor episod venous thromboembol improv screen cteph necessari creat algorithm monitor patient pe provid educ activ includ media creat materi patient access inform regulatori document design circl respons specialist engag long term monitor patient pe educ program need primari care physician cardiologist physician come field view patient cteph introduct program creat expert center monitor manag patient possibl perform ventil perfus lung scintigraphi cardiopulmonari stress test ct right heart catheter seem import build cooper ministri health russia order creat special protocol procedur manag patient pe cteph

D006976;D000086382;D011655

T047;T046;T067

36,286,753

acut decompens heart failur state problem present key aspect manag patient acut decompens heart failur lead improv clinic outcom describ exist problem possibl solut

D006333

T047;T046

36,286,622

explor epigenom dataset chipseek mani aspect life epigenet alter phenotyp without chang sequenc play essenti role biolog function vast number epigenom dataset emerg result advent next generat sequenc annot comparison visual interpret epigenom dataset remain key aspect comput biolog chipseek bioconductor packag perform analys among variabl epigenom dataset fundament function chipseek includ data prepar annot comparison visual explain articl chipseek freeli avail open sourc packag may found https wwwbioconductororgpackageschipseek wiley period llc basic protocol chipseek epigenom dataset prepar basic protocol annot epigenom dataset basic protocol comparison epigenom dataset basic protocol visual annot result basic protocol function analysi epigenom dataset basic protocol genom wide locus specif distribut epigenom dataset basic protocol heatmap metaplot epigenom dataset

D057890;D012984

T090;T170;T091;T073

36,286,610

aryl danc reaction arylbenzoheterol report migrat aryl danc reaction aryl group heterol alcl effici convert c arylheterol c arylheterol depend electron densiti substrat convers c c arylheterol also possibl catalyt zn otf one pot aryl danceacyl bromin arylationaryl danc cascad also demonstr

D003615

T056

36,286,606

multiplex singl nucleus rna sequenc use lipid oligo barcod protocol describ robust pipelin simultan analyz multipl sampl singl nucleus sn rna seq cdna obtain singl sampl label lipid coupl oligonucleotid barcod x genom nuclei mani individu sampl pool togeth simultan process cdna librari construct subsequ dna sequenc previous protocol use lipid coupl oligonucleotid barcod optim analysi sampl consist viabl cell protocol optim analys quick frozen cell sampl protocol ensur effici recoveri nuclei incorpor high sucros buffer solut includ track dye trypan blue nuclei isol protocol also describ procedur remov singl nuclei artifact remov cell debri prior singl nuclear fraction protocol inform use comput tool filter poor label nuclei assign sampl ident use barcod uniqu molecular identifi umi read count percentag comput pipelin applic either cultur primari fresh frozen cell regardless cell type speci overal protocol reduc batch effect experiment cost enhanc sampl comparison wiley period llc basic protocol label cell lipid oligo barcod generat multiplex singl nucleus rna seq librari basic protocol bioinformat deconvolut multiplex snrnaseq librari

D014343;D013395

T123;T121;T130;T109

36,286,602

multicent random doubl blind placebo control crossov trial evalu efficaci safeti zolmitriptan nasal spray acut treatment migrain patient age year open label extens evalu efficaci safeti zolmitriptan nasal spray zns acut treatment migrain headach patient age year

D059085;D008881

T047;T074

36,286,601

digit headach self manag intervent patient primari headach disord systemat review random control trial articl systemat review empir literatur examin efficaci digit headach manag intervent patient primari headach disord

D000073278;D051270

T033;T058;T047

36,286,600

narrat review peripher nerv block manag headach provid overview current avail literatur peripher nerv block manag migrain headach disord adult

D003027;D008881;D020773;D009437

T184;T047

36,286,595

pneumonia subsequ risk dementia evid japan gerontolog evalu studi recent sever studi report pneumonia might increas risk cognit declin dementia due increas frailti

D000073496;D003704;D011014

T184;T050;T033;T047;T046;T048

36,286,593

total synthesi cordycep militari glycan via stereoselect orthogon one pot glycosyl glycosyl strategi cordycep militari glycan potent antioxid activ effici collect synthes synthet approach featur follow stereoselect orthogon one pot glycosyl strategi tran cis glycosid linkag merg reagent modul remot anchimer assist rmraa glucosyl strategi dmf modul glucosyl converg orthogon one pot assembl target tridecasaccharid

D032661

T004

36,286,590

interfer glucos bioavail tumor engin biohybrid potenti target uptak antitumor nanodrug chemotherapi efficaci nanodrug restrict poor tumor target uptak engin biohybrid live materi design ecn hpb construct integr paclitaxel bay bound human serum albumin nanodrug hpb escherichia coli nissl ecn due inher tumor tropism ecn ecn hpb could activ target tumor site competit depriv glucos bacteri respir thus albumin would use altern nutrient sourc tumor metabol signific promot intern hpb tumor cell subsequ bay intern along hpb nanodrug would depress glucos uptak tumor cell via inhibit glucos transport glut togeth declin glucos bioavail tumor cell would activ promot macropinocytosi amp activ protein kinas ampk depend manner result uptak hpb tumor cell boost therapeut outcom paclitaxel

D009369;D004927;D053758

T047;T191;T073

36,286,589

health secur plan develop cameroon nation action plan health secur health secur plan process transform recommend various evalu prioriti action strengthen countri capac emerg prepared use one health approach although world health organ develop mani tool facilit plan process nation action plan health secur naph across various compon seri multisector workshop still need complet process articl report process develop cameroon naph propos innov solut improv process naph develop process conduct may decemb naph framework adapt local context guid process plan matrix use plan activ naph cost tool use facilit cost exercis total joint extern evalu recommend translat activ includ cameroon naph among activ major medium prioriti total cost year naph us almost half budget alloc activ prevent categori third alloc detect categori top cost driver immun nation laboratori system antimicrobi resist naph inform policymak plan activ fund need fast track develop health secur capac run gap fund address resourc map exercis improv overal plan process web base support solut stakehold select menu recommend joint extern evalu develop naph develop improv naph develop process

D007391;D000890

T121;T064

36,286,588

promis emerg nanobiotechnolog vivo applic implic safeti secur nanotechnolog multidisciplinari field base exploit uniqu physicochem properti nanoparticl nps nanoscal materi open new realm possibl biolog research biomed applic develop deploy mrna np vaccin covid exampl may revolution vaccin therapeut howev regulatori ethic framework protect health safeti global communiti environ lag particular nanotechnolog gear toward biolog applic ie bionanotechnolog articl comprehens attempt illustr breadth promis bionanotechnolog develop may present futur safeti secur challeng specif address current advanc streamlin develop engin nps vivo applic provid discuss nano bio interact np vivo deliveri nanoenhanc human perform nanomedicin impact nps human health environ

D000086663;D000086382

T200;T047;T067

36,286,580

light induc iron catalyz trifluoromethyl thiolat alken seri novel trifluoromethyl thiolat alken realiz use visibl light drive forc iron salt catalyst bis trifluoromethyl compound could obtain moder good yield multicompon protocol proceed atom econom way broad substrat scope biolog activ chemic also toler provid desir product suggest catalyt protocol could viabl late stage modif pharmaceut discoveri last flow setup synthesi desir product success appli gram scale indic synthet power reaction industri applic

D000475;D007501

T123;T196;T121;T109

36,286,579

accept implant hiv treatment young children perspect health care provid johannesburg south africa south africa less half children receiv antiretrovir therapi viral suppress adher challeng includ poor palat drug high pill burden subcutan implant offer long act altern daili oral dose regimen may improv outcom children live hiv clwh qualit depth interview conduct health care provid hcps johannesburg south africa interview audio record transcrib data code analyz use nvivo softwar ground theori approach hcps welcom implant option clwh perceiv benefit includ fewer clinic visit improv adher normal live clwh concern includ pain insert remov potenti stigmat caregiv like reject biodegrad implant singl small non transpar rod flexibl prefer particip hcp train earli outreach mitig potenti misinform implant caregiv fear biodegrad implant emphas engag caregiv clwh requir ongo

D015658

T047

36,286,578

episod use pre exposur prophylaxi among young cisgend women siaya counti kenya concept season risk promot use pre exposur prophylaxi prep period hiv risk prep guidelin align daili use women vagin sex risk period daili use day last potenti exposur recommend howev start season risk guidelin vari time protect unknown remain pharmacolog research prep protect popul iter research prep persist use photovoic depth interview identifi ineffect pattern prep use base current guidelin routin episod use among young cisgend women ycw siaya counti kenya group n particip mix group n particip photovoic activ ycw take prep femal peer particip explain ycw associ hiv risk sexual behavior male partner frequent travel home prep consid unnecessari partner away perceiv risk ycw start prep around day partner return heighten risk percept among ycw interview n near partner travel week month time one third women report stop prep partner absenc start soon immedi upon partner arriv home addit research critic need better inform prep guidelin decis adolesc girl young women make use prep base risk context interim counsel current dose guidanc stop start prep within season risk need

D065129;D019380;D015658

T061;T121;T047

36,286,577

factor associ post exposur prophylaxi awar among latino sexual minor men south florida despit efficaci biomed hiv prevent tool post exposur prophylaxi pep pre exposur prophylaxi prep insuffici scale dissemin especi among margin subgroup face substanti hiv dispar given minim literatur avail pep among latino sexual minor men lsmm cross section secondari analysi explor factor associ pep awar among group lsmm live south florida us hiv epicent parent studi examin pattern engag prep behavior health treatment servic among lsmm n current secondari analysi n identifi factor associ pep awar use three method stochast search variabl select participatori data scienc literatur review model use linear regress particip report littl awar pep initi studi simpl linear regress model suggest higher prep knowledg b se p hiv knowledg b se p prep self efficaci b se p high perceiv communiti norm hiv test b se p associ lsmm greater pep awar ident affirm associ less pep awar b se p result suggest util three prong variabl select approach address gap pep awar use among lsmm live us hiv epicent support end hiv epidem goal

D015658;D065129;D000072339

T061;T047;T098

36,286,576

intens puls light therapi inhibit meibomian gland inflamm untarget metabolom analysi meibomian gland secret object assess inhibitori effect intens puls light ipl meibomian gland mg inflamm background ipl treatment effect dri eye diseas ded caus meibomian gland dysfunct mgd howev anti inflammatori regener stimul effect ipl mgd remain unclear moreov studi inflammatori metabolit mg secret lack method six patient ded administ two ipl treatment ocular surfac diseas index osdi questionnair use assess ded mgd sign includ degre obstruct secret atrophi mg tear film break time tbut assess treatment determin ipl treatment induc chang metabolit liquid chromatographi tandem mass spectrometri lc msms use analyz mg secret result data gather first treatment time week second treatment time b averag osdi score show signific decreas time b measur respect besid statist signific differ observ mg sign treatment degre obstruct improv secret becam thinner tbut signific increas normal rang lc msms led identif differenti metabolit upregul eg estradiol coenzym q azela acid downregul eg prostaglandin hydroxyeicosatetraeno acid arachidon acid kyoto encyclopedia gene genom pathway enrich analysi show differenti metabolit involv steroid hormon biosynthesi conclus periorbit ipl treatment improv chronic inflamm mg promot normal secret steroid hormon biosynthet pathway may activ particip anti inflammatori effect

D062325;D000080343

T061;T047

36,286,575

q switch nm nd yag laser rejuven photoag skin rat downregul mir b p background q switch nm nd yag laser qsnyl effici rejuven photoag skin microrna mirna particip process object studi aim explor effect qsnyl mir b p tgf beta receptor ii tgfbr smad photoag skin rat method relationship mir b p tgfbr hacat cell detect real time pcr western blot skin photoag model establish wistar rat use ultraviolet uv radiat uvr dermoscopi hematoxylin eosin stain sirius red stain hydroxyprolin content use observ effect uvr rat skin qsnyl use skin rejuven express cola tgfb tgfbr smad smad smad detect real time pcr andor western blot result tgfbr specif target mir b p skin hacat cell photoag skin rat qsnyl treatment upregul cola tgfbr downregul smad mir b p conclus show first time qsnyl treatment rejuven photoag rat skin regul tgfbr smad downregul mir b p assist process target upregul tgfbr

D053844;D015595;D035683

T123;T073;T042;T033;T114;T074

36,286,574

custom photobiomodul modul pain alter thermographi pattern patient knee osteoarthr random doubl blind pilot studi background photobiomodul therapi pbmt modul wide varieti biolog process lead anti inflammatori analges effect understand mechan under therapeut effect pbmt remain challeng due vari outcom observ wavelength dosag site applic research group dedic close attent custom individu dosimetri pbmt protocol preliminari data show use individu treatment could solv contradictori result report previous studi base literatur preliminari data light absorpt goal present pilot determin whether individu dosimetri feasibl method assist osteoarthr oa pain control method parallel two arm control pilot studi aim assess whether person pbmt effect treatment pain chronic knee oa thirti one patient random alloc treatment placebo group sham irradi treatment procedur perform twice week week pbmt appli use nm continu wave total j session individu dosimetri chosen base patient bodi mass index skin color qualiti life qol questionnair serumurin analys perform treatment examin particip blind group alloc result pain score reduc signific th th th session remain lower week posttherapi treatment group compar placebo group moreov treatment group result improv qol questionnair score dopamin level microcircul conclus present result provid initi evid custom photobiomodul pbm reduc pain level short medium term patient symptomat knee oa compar placebo group furthermor provid evid custom pbm abl improv qol patient

D020370

T047

36,286,571

melanoma investig primari treatment melanoma relat common diagnosi primari specialist health servic ongo research new evid base mean recommend investig treatment continu chang lead uncertainti among doctor treat patient group regular clinic review give summari latest recommend primarili aim general practition dermatologist doctor local hospit

D008545;D010820;D012878

T191;T097

36,286,565

woman delus hallucin dyston eye movement woman earli rare neurogenet syndrom admit psychiatr depart suspicion psychot disord cours ill patient suffer episod involuntari eye movement behaviour chang psychot symptom difficult treat

D011618;D004421

T184;T048

36,286,559

breastfeed treatment multipl sclerosi monoclon antibodi therapi effect multipl sclerosi small amount antibodi transfer breast milk even though approv product descript advis breastfeed medicin treatment sever effect ms drug compat breastfeed

D001942;D009103

T055;T058;T040;T047

36,286,556

histopatholog reassess melanoma melanocyt skin lesion excis histopatholog assess melanoma melanocyt skin lesion difficult vari pathologist

D004416;D008545;D012878;D009506

T191

36,286,547

increas detect carbapenemas produc enterobacteral bacteria latin america caribbean covid pandem countri latin america caribbean report clinic emerg carbapenemas produc enterobacteral previous character local increas preval carbapenemas previous detect co product multipl carbapenemas isol increas like fuel chang relat covid pandem includ empir antibiot use potenti covid relat bacteri infect healthcar limit result rapid rise covid case strengthen antimicrobi resist surveil epidemiolog research infect prevent control program antimicrobi stewardship clinic set help prevent emerg transmiss carbapenemas produc enterobacteral

D000086382

T047;T067

36,286,543

acetylpyridin tissu patern bchi derivat enabl high coverag lipid cc locat resolv ms imag biolog tissu unsatur lipid contain singl carbon carbon doubl bond cc within tissu close associ various type diseas mass spectrometri imag msi use studi spatial distribut lipid cc locat isom tissu section howev comprehens character lipid cc locat isom use msi remain challeng herein establish tissu charg switch patern bchi pb derivat method use acetylpyridin ap reaction reagent use detect assign cc locat glycerophospholipid gpls well neutral lipid fatti acid fas experiment workflow use matrix assist laser desorptionion maldi msi high coverag mono poli unsatur cc locat isom among various lipid class includ fa phosphatidylcholin pc sulfatid shexcer distinct region mous brain kidney visual use maldi msms imag method also appli map spatial distribut lipid cc locat isom alzheim diseas ad mice model first time provid new tool studi relationship distribut lipid structur divers neurodegen diseas

D053719;D020404

T063;T109